Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2022-03-18 Environmental & Social …
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团2021年度社会责任报告
Environmental & Social Information Classification · 100% confidence The document is titled as the "年度社会责任报告" (Annual Social Responsibility Report) for the year 2021 by 昆药集团股份有限公司 (Kunming Pharmaceutical Group Co., Ltd.). It explicitly states it is the company's 11th social responsibility report, covering the period from January 1, 2021 to December 31, 2021. The content includes detailed discussions on the company's social responsibility practices, environmental and social initiatives, governance, and sustainability efforts. It references ESG factors and sustainability standards such as GRI Standards and CASS-CSR4.0. The document is comprehensive and contains substantive data and narrative on environmental, social, and governance performance rather than financial results or management discussion of financials. It is not an announcement or a brief summary but a full report. Therefore, the document fits the category of Environmental & Social Information (Code: SR).
2022-03-18 Chinese
昆药集团2021年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制评价报告' which translates to '2021 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2021, including financial and non-financial internal control defects, their identification, and rectification status. The document is a detailed report on internal control evaluation, which is a type of audit-related report focusing on internal controls and their effectiveness. It is not an announcement or a brief summary but a substantive report containing evaluation conclusions and standards. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations, excluding full annual reports. The document length (3635 characters) is sufficient for a detailed report but not a full annual report. Hence, the classification is AR with high confidence. FY 2021
2022-03-18 Chinese
昆药集团独立董事关于公司十届四次董事会相关事项的事前认可及独立意见
Board/Management Information Classification · 95% confidence The document contains independent directors' opinions and pre-approval statements related to the company's board meeting agenda items, including approval of the 2022 guarantee plan, appointment of the 2022 audit firm, internal control evaluation report for 2021, profit distribution plan for 2021, and other governance matters. It references compliance with laws, regulations, and company articles, and discusses board and shareholder meeting submissions. The document is not a full annual report or audit report but rather opinions and approvals related to board meeting agenda items. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short and focused on board meeting matters, not a full financial report or audit report. Therefore, the best classification is MANG with high confidence.
2022-03-18 Chinese
昆药集团股份有限公司股东大会议事规则
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of Kunming Pharmaceutical Group Co., Ltd., revised in March 2022. It details the procedures, rights, and regulations governing the conduct of shareholders' meetings, including notice requirements, proposal submissions, voting procedures, meeting records, and disclosure obligations. It does not contain financial statements, audit opinions, or earnings data. Instead, it is a governance document outlining internal rules and processes related to shareholder meetings. Therefore, it fits best under Governance Information (CGR). The document length (8028 characters) and content confirm it is a full procedural guideline, not a brief announcement or a report publication notice.
2022-03-18 Chinese
昆药集团关于2022年度融资额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the company's financing quota for the year 2022. It details the proposed financing amounts, purposes, and authorization requests for the board and shareholders. The document does not contain financial statements or detailed financial results but focuses on the company's plans to apply for financing and the related approvals needed. This fits the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is short (1378 characters), but it is not merely announcing the publication of a report; it is itself the announcement of financing plans. Therefore, the correct classification is CAP with high confidence.
2022-03-18 Chinese
昆药集团关于2021年度利润分配方案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2021 annual profit distribution plan of Kunming Pharmaceutical Group Co., Ltd. It details the dividend payout per share, total dividend amount, and the approval process including board and independent directors' opinions. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related corporate governance steps. It is a formal announcement of a dividend plan, not the full annual report or earnings release. Therefore, it fits the category of Notice of Dividend Amount (DIV). The document length is 1862 characters, which is consistent with an announcement rather than a full report.
2022-03-18 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.